SenesTech (NASDAQ: SNES) is one of 191 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare SenesTech to related businesses based on the strength of its institutional ownership, risk, valuation, earnings, profitability, dividends and analyst recommendations.
Institutional & Insider Ownership
15.3% of SenesTech shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 27.4% of SenesTech shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares SenesTech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for SenesTech and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SenesTech currently has a consensus price target of $8.50, suggesting a potential upside of 1,207.49%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 19.82%. Given SenesTech’s stronger consensus rating and higher probable upside, research analysts clearly believe SenesTech is more favorable than its competitors.
Valuation and Earnings
This table compares SenesTech and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SenesTech Competitors||$227.13 million||-$38.54 million||-52.23|
SenesTech’s competitors have higher revenue, but lower earnings than SenesTech. SenesTech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
SenesTech beats its competitors on 7 of the 12 factors compared.
SenesTech Company Profile
SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.